altering their safety profile. Extractables refer to the chemical substances that can be extracted from the packaging materials under aggressive conditions, while leachables are substances that may migrate into the drug product under normal storage and use conditions. In the context of biologics, understanding E&L is essential not just for compliance but as a proactive measure to ensure product integrity.

In designing E&L studies, it is fundamental to note the following considerations:

• Material Characterization: Every component of the device should be scrutinized, as the materials used will directly affect the extractables profile. This includes polymers, metals, and coatings.
• Analytical Techniques: Utilize sophisticated analytical methods such as Gas Chromatography-Mass Spectrometry (GC-MS) and Liquid Chromatography-Mass Spectrometry (LC-MS) to analyze the extractables and leachables from the combination products.
• Impact on Biologics: Assess how leachables can interact with the biologics in terms of protein stability, efficacy, and immunogenicity; conducting stability studies to monitor these interactions is crucial.
• Regulatory Guidelines Compliance: Ensure the E&L studies are in compliance with guidelines provided by regulatory bodies, such as those from the FDA, EMA, and ICH.

Regulatory Framework for Combination Products

The regulatory environment governing combination products varies by region, necessitating a comprehensive understanding of both US and EU regulations. In the US, combination products are classified into three categories: drug-device combinations, biologic-device combinations, and drug-biologic combinations. Each is governed by different parts of the FDA regulations. For biologics, guidance on adequate study design, specifically for E&L, is outlined in the FDA’s Guidance for Industry on Container Closure Systems for Packaging Human Drugs and Biologics.

Similarly, in the EU, the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Medical Devices Regulation (IVDR) outline the necessary compliance frameworks that manufacturers must adhere to when developing combination products. Key considerations include:

• Classification: Proper classification determines the applicable regulations and requirements. Understanding whether the primary mode of action is attributed to the device or the biologic is fundamental.
• Quality Management Systems (QMS): Both the biologic and device components must be developed under robust QMS standards, ensuring consistent product quality.
• Post-Market Surveillance: Implementing a robust post-market surveillance system can help capture data on the safety and efficacy of combination products post-approval.

Study Design Considerations for E&L Testing

When devising a study for E&L testing, it is essential to have a clear framework. Below is a step-by-step guide to conducting E&L studies for combination products:

Step 1: Define Product Components and Materials

The first step involves identifying all components involved in the combination product. This should comprehensively cover every aspect of the device, including:

• Polymeric materials
• Metals and alloys
• Gaskets and seals
• Coatings used on surfaces
• Any adhesives or bonding agents

Consider maintaining a record with detailed specifications and characteristics of each material to facilitate relevant E&L studies.

Step 2: Selection of E&L Testing Conditions

Choosing appropriate extraction conditions is critical. Conditions should mimic realistic exposure scenarios, aligning with the intended storage and use conditions of the biologic. The following factors should inform selection:

• Temperature: Elevated temperatures may accelerate leaching; testing at different temperatures helps assess the robustness of the product.
• Contact Time: Consider how long the biologic will be in contact with the packaging material at various usage points.
• Solvent Selection: Different solvents can extract different substances; ensure that the solvents chosen closely match those expected in real-world scenarios.

Step 3: Analytical Method Development

Once conditions for testing have been established, developing analytical methods to characterize the extractables and leachables is critical. Key aspects of method development include:

• Method Sensitivity: Ensure that the analytical method can detect low levels of leachables that could jeopardize product safety.
• Method Specificity: The chosen method must be specific enough to distinguish between background noise and relevant E&L.
• Validation: The methods should be validated in accordance with regulatory guidance to ensure reliability and reproducibility.

Step 4: Interpret and Assess Results

Analysis results must then be interpreted carefully to assess potential risks posed by leachables on the biologic. This requires close collaboration between toxicology and packaging development teams. Key points for assessment include:

• Toxicological Assessment: Evaluate the potential toxicity of identified leachables using toxicological databases and literature. This may involve in silico models, in vitro assays, or even in vivo studies, depending on the leachables and their expected clinical relevance.
• Risk Assessment: Conduct a cumulative risk assessment for all identified leachables. Consider potential interactions with the biologic and cumulative effects from multiple components.
• Regulatory Submission Preparation: Results from E&L studies should be strategically presented in regulatory submissions, ensuring transparency and clarity about product safety.

Documentation and Communication in E&L Studies

The outcomes of E&L studies must be meticulously documented, serving not only compliance purposes but also facilitating communication across development teams. Key documentation aspects include:

• Test Protocols: Clear and detailed test protocols outlining methodologies and procedures should be drafted and stored for future reference.
• Study Reports: Comprehensive reports summarizing findings, assessments, and implications should be compiled and readily accessible to regulatory bodies and stakeholders.
• Change Management: Document any changes to materials or formulations promptly to ensure ongoing compliance and risk assessment alignment.

Conclusion

The design considerations for E&L studies in combination products containing biologics are integral to ensuring regulatory compliance and product safety. By adhering to a systematic approach and collaborating across functional teams, CMC leads and their teams can effectively navigate the complexities of E&L studies. Understanding the regulatory frameworks in the US and EU, along with executing well-planned studies, will not only mitigate risks but also foster the successful development of safe and effective biologic combination therapies.